Report – FDA FY2020 Drug Observations and Trends

By Barbara W. Unger

Topics of this report include:

• Data from FY2020 FDA drug GMP inspections
• Trends from five years of GMP inspections
• Conclusions drawn from an analysis of drug inspection data